Plazomicin

Drug Profile

Plazomicin

Alternative Names: [14C]-plazomicin; ACHN-490; Plazomicin sulfate

Latest Information Update: 18 Jul 2017

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Achaogen
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bacteraemia; Nosocomial pneumonia; Pyelonephritis; Urinary tract infections
  • Preclinical Gram-negative infections; Respiratory tract infections; Tularaemia; Yersinia infections

Most Recent Events

  • 18 Jul 2017 Achaogen completes a phase I trial in Healthy volunteers in USA (NCT03177278)
  • 06 Jun 2017 Achaogen initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT03177278)
  • 05 Jun 2017 Updated efficacy data from the phase III EPIC and CARE trials in Urinary tract infections and Bacteraemia presented at the American Society for Microbiology Microbe Annual Meeting (ASM-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top